Standard Colonoscopy for Adenoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Adenoma+2 More
Standard Colonoscopy - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

During colonoscopy, the endoscopist will document colonoscopy indication; BBPS score; withdrawal time; adenoma and polyp detection rate at index and follow-up colonoscopy; completeness of polypectomy; polyp location, size, surface, morphology (Paris classification), histopathology; complications.

Eligible Conditions

  • Adenoma
  • Colorectal Carcinoma

Treatment Effectiveness

Study Objectives

2 Primary · 11 Secondary · Reporting Duration: 1 year

1 year
Adenoma detection rates (ADR) and advanced adenoma detection rates at follow-up
Rate of T-MAN and metachronous HRA detection for the serrated lesion (SL) and HGD groups
Rate of T-MAN detection according to number, size, location, and dysplasia status of index SSPs
Rate of T-MAN detection for concomitant index SSP+low-risk adenoma (LRA); index SSP+ high-risk adenoma (HRA); index SSP alone
Rate of TMAN detection after index detection of serrated lesions
Rate of metachronous HRA detection according to number, size, location, and dysplasia status of index SSPs
Rate of metachronous HRA detection for index HGD according to number, size, location, of index HGD
Rate of metachronous HRA detection for index HGD alone
Rate of metachronous HRA for concomitant index SSP+LRA; index SSP+HRA; index SSP alone; index SSP all synchronous findings included; index TSA all synchronous findings included
Rate of metachronous advanced SL and metachronous HRA detection for the serrated lesion (SL) group
Rate of metachronous high-risk SL detection according to number, size, location, and dysplasia status of index SSPs
Rate of metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD)
Rate of metachronous high-risk serrated lesion (SL) for concomitant index SSP+LRA; index SSP+HRA; index SSP alone; index SSP all synchronous findings included; index TSA a ll synchronous findings included

Trial Safety

Trial Design

1 Treatment Group

Colonoscopy
1 of 1
Experimental Treatment

730 Total Participants · 1 Treatment Group

Primary Treatment: Standard Colonoscopy · No Placebo Group · N/A

Colonoscopy
DiagnosticTest
Experimental Group · 1 Intervention: Standard Colonoscopy · Intervention Types: DiagnosticTest
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard Colonoscopy
2013
Completed Phase 3
~9360

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Closest Location: Centre Hospitalier de l'Université de Montréal · Montréal, Canada
Photo of quebec 1Photo of quebec 2Photo of quebec 3
2012First Recorded Clinical Trial
1 TrialsResearching Adenoma
50 CompletedClinical Trials

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
319 Previous Clinical Trials
111,519 Total Patients Enrolled
3 Trials studying Adenoma
1,132 Patients Enrolled for Adenoma
Daniel von Renteln, MdPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.